Hot Investor Mandate: Multi-Faceted iBank Invests in Seed to Series A Stage Life Science Companies, Capable of Investing $10M+

14 Mar

An investment bank based in the US actively seeks new investment opportunities. The firm does not act as a traditional investment bank, as they participate in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public market. The firm generally does not look at digital health. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes their sister company to further analyze company technologies and IPs. The firm can fund from $5M-12M USD from Seed to Series A rounds with preference in US-based companies, though open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 
The firm works closely with companies and founder and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Fund and Venture Builder Invests in Global Medtech Companies Advancing the Field of Neurotechnology 

14 Mar

A venture builder and fund is looking to invest in US-based neurotechnology device companies advancing transformative diagnostics and therapies. The firm offers 3 different opportunities to support companies: (1) grants to academic researchers whose research aligns with the firm’s interests, (2) venture creation where the firm helps founders create, augment, and support companies, and (3) traditional equity investing. The firm engages in Pre-Seed to Series A rounds with typical check sizes ranging from $250k-2M USD. 
 
The firm primarily invests in medical devices that address stress and anxiety, sleep, and pain. The firm is open to working with companies from in-development stages. The firm is also open to take a leap on long-shot technologies that have potential to make significant changes in the neurotechnology space. 
 
The firm does not have specific management team requirements and typically does not lead. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

Hot Investor Mandate: Large Biopharmaceutical Seeks In-Licensing Opportunities in Oncology and Immunology Across the Globe

14 Mar

Founded in 2010, with headquarters in Shanghai (China) and additional operations in USA, a global biopharmaceutical company has a vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology and immunology. The firm has launched 5 products in China, 1 in overseas markets (including EU) during past 4 years. 
 
The firm is seeking to in-license innovative assets and platforms in oncology that have synergies with the company’s current portfolio, in addition to seeking development and commercial partners for our oncology programs. 

The firm has no specific requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Announcing the Speaker Lineup at RESI South

7 Mar

By Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

Joey-New-Headshot

RESI South is rapidly approaching, taking place in person on March 25 in Atlanta at The Whitley Buckhead Hotel, followed by two days of virtual partnering on March 26-27. For this highly anticipated conference, LSN’s Investor Research Team has curated a lineup of 7 panels covering a wide range of topics relevant to early-stage investments and innovations.

At RESI South, we have a series of panels that feature key players in the startup investment ecosystem, including Corporate Venture Capital and Seed Funds. The panelists will delve into their investment and partnership strategies, how they evaluate prospects, manage relationships with their early-stage portfolio, and their unique position in the ecosystem, among other topics.

Other panels will focus on emerging sectors that have been gaining interest and momentum, such as Digital Health, AI in Healthcare, CNS Diseases, Longevity, and Chronic Disease Management. These panels will feature investors who have been actively following and allocating in these respective verticals. They will provide insights into cutting-edge innovations, the latest investment trends, the importance of these technologies, and how these markets will evolve in the future.

We are honored to be joined by a diverse group of panelists, each bringing unique backgrounds and experiences. Through organizing these panels, our goal is to foster communications, bridge the gap between entrepreneurs and investors/strategic partners, and assist founders and CEOs in navigating their fundraising and business development journey in this highly competitive landscape. Don’t miss the opportunity to hear from and connect with seasoned investors and executives at these RESI panels.

Here are the speakers for RESI South 2024:

Peter Alff
Senior Venture Partner
Orange Grove Bio
Irene Blat
Sr. Dir. Search & Evaluation, Oncology
Servier
Natasha Bonett DeLong
Portfolio Manager
Rex Health Ventures
Mark Bouzyk
President & CSO
AllaiHealth
Justin Burns
Vice President, Venture Development
GRA Venture Fund, LLC
Rowan Cade
Program Manager, BARDA Ventures
Division of Research Innovation and Ventures (DRIVe)
Tom Callaway
Founder
Life Science Partner
Nicolas Cindric
Partner
Yahara Ventures
Drew Cutshaw
Senior Associate & Medical Officer
Pappas Capital
Sinclair Dunlop
Managing Partner
Epidarex Capital
Martin Gershon
Managing Partner and CIO
Endeavor Venture Funds, Senior Executive Investor-in-Residence Techstars
Deborah Hemingway
Managing Partner
Ecphora Capital
Ray Jang
Principal
Primetime Partners
Jennifer Jordan
Venture Partner
iGlobe Partners
Nancy Torres Kaufman
CEO
Beacon Capital LLC
Sarah Kleinpeter
Global Vice President Alzheimer’s Disease
Novo Nordisk
Jason Kuo
Senior Associate & Lead Healthcare Investor
Tech Square Ventures
Mankit Law
Director, Worldwide Business Development
GlaxoSmithKline (GSK)
Michelle (Waye) Leeuwon
Program Manager for Product Development
Cancer Prevention and Research Institute of Texas (CPRIT)
Ron Levin
Managing Partner
Alumni Ventures
Andy Merken
Partner, Corporate & Securities Co-Chair, Life Sciences
Burns & Levinson
Ross O’Brien
Founder & Managing Partner
Bonaventure Equity, LLC (BVE)
Allyson Plosko
Partner
SpringTime Ventures
William Plumer
Managing Partner
Bullet Partners
Preetha Ram
Managing Partner
Pier 70 Ventures
Thomas Saylor
Chief Executive Officer, Serial Enterpreneur
NeuroAcoustics
Katerina Stroponiati
Co-Founding Partner
Monday Capital
Nathan Styles
Executive Director of McQuade Center for Strategic R&D
Otsuka Pharmaceutical
Jim Tobin
VP, Cardiovascular & Metabolism Scientific Innovation
Johnson & Johnson Innovation
Liz Todia
Principal
Mutual Capital Partners
Robert Tucci
Managing Director
Texas HALO Fund
Dave Vreeland
Senior Managing Partner
Caduceus Capital Partners

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

What Makes RESI Stand Out

7 Mar

By Cameron Hurlburt, Director of Business Development, LSN

The RESI South Conference is a hybrid event, with an in-person day on March 25th at the Whitley Atlanta Buckhead Hotel in Atlanta, GA, followed by two virtual days on March 26th and 27th. Life Science Nation expects 300+ life sciences startups, investors, and strategic partners to mingle for dynamic networking opportunities. The RESI South Partnering Platform opened on March 4th, connecting CEOs with 150+ early-stage investors. Tailored matchmaking in sectors like therapeutics, medical devices, diagnostics, and digital health awaits.

To learn more, please watch the RESI Overview Webinar hosted by our Chief Conference Officer and VP of Investor Research, Claire Jeong. In this 10-minute video, Claire provides an overview of the RESI conference series, explains what makes RESI South unique, and, most importantly, how the RESI conferences stand out from other partnering events.

Click the video to watch:

Register-now-button-new

RESI-South-2024_02062024.

Tips for Successful Partnering at RESI South 

7 Mar

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti

Partnering conferences are an important part of an early-stage company’s journey to raising capital and achieving your fundraising goals. Life Science Nation (LSN) hosts the RESI conference series to provide partnering opportunities with investors and strategic partners. Additionally, LSN provides support to Founders and CEOs to get prepared for meetings by putting their best foot forward and prepping them with the tools necessary to get there. A key tool for making the most of our next conference, RESI South, is the RESI Survival Guide.

The RESI Survival Guide covers the 5 major steps to finding success at RESI:

  • Build a Comprehensive Partnering Profile
  • Develop your Executive Summary
  • Refine your Pitch Deck
  • Craft your Meeting Request Message
  • Outline a Follow-up Strategy

Read detailed explanations of each step and examples of executive summaries and meeting requests in the RESI Survival Guide.

Partnering for RESI South is LIVE as of Monday, March 4th. Make sure to set your schedules up and make time slots available and accept and send meeting requests to secure some meetings on your calendar.

LSN provides Partnering Tutorial webinars, you can signup to join the live webinar and participate in the Q&A on March 14, register here. The Partnering Tutorial is a terrific way to figure out how to navigate LSN’s RESI partnering system and learn insights on outreach strategy to secure investor and strategic partner meetings that are the right fit for you.

If you have any questions about getting prepared for RESI South or wish to have a consultation on your marketing materials, reach out to RESI@lifesciencenation.com and your Business Development representative will schedule some time with you to review. Registration is still open to attend RESI South, with options to attend both in-person and virtually. Happy Partnering!

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Hot Investor Mandate: VC in Western Europe Invests Up to €20M in US & Europe-Based Devices, Diagnostics, and Digital Health Companies 

7 Mar

A venture capital firm headquartered in Western Europe invests in healthcare companies with typical check size ranging from €1-20M EUR, participating starting from the 2nd or 3rd rounds of financing until Series B. The firm focuses on companies in the U.S. or Europe. 
 
The firm invests in diagnostics, digital health, and medical devices. The firm does not invest in drugs, biotech, or therapeutics. The firm invests in companies in the in-development or clinical stages. The firm is indication-agnostic. 
 
The firm does not have specific management team requirements. The firm typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.